Myriad Genetics, Inc. (MYGN) Stock Price & Analysis

Myriad Genetics, Inc. (MYGN) is trading at USD 5.73, down 0.52% today, as of October 23, 2026 at 15:07 UTC (US market open; quotes may be delayed), according to Nexqual market data.

MYGN last closed at USD 5.76; today's session has ranged USD 5.6–5.77 on volume of 341,296 shares. Market capitalization is $548.07M, with a 52-week range of USD 2.74–8.5 (NMS). Source: Nexqual, retrieved October 23, 2026 at 15:07 UTC.

Also available as compact Markdown for AI agents: nexqual.com/MYGN.md

Key facts (MYGN)

• Last four reported quarters (through Jun 30, 2026): revenue $807M, net income -$113M (-14.0% margin) (SEC filings).
• Insider open-market sales, last ~7 months: 1 Form 4 filings, $67K; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Insider open-market purchases, last ~7 months: 1 Form 4 filing, $28K; 0 by opportunistic insiders, 0 by routine insiders.
• Analysts: Hold (mean 3.22 on a 1–5 scale) (9 analysts), mean target USD 4.49 (range 2.5–8).
• Total return with dividends: 1Y -28.8% vs S&P 500 +14.8%; 5Y -81.4% vs S&P 500 +77.5%.
• Next earnings: 2026-11-04, EPS estimate USD -0.2, revenue estimate $191M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (MYGN)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (MYGN)

P/S 0.7x · P/B 1.8x · Earnings yield -20.54%

Insider sales (SEC Form 4, open-market, last ~7 months) (MYGN)

1 of 1 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Insider purchases (SEC Form 4, open-market, last ~7 months) (MYGN)

1 purchase, $28K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.

Analysts (MYGN)

Consensus Hold (mean 3.22 on a 1–5 scale), 9 analysts; mean target USD 4.49 (low 2.5, high 8).

Rating changes, last 120 days:

Total return (dividends reinvested) (MYGN)

MYGN revenue by product line (quarter ended Jun 30, 2026)

MYGN revenue by region (quarter ended Jun 30, 2026)

As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).

MYGN suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 24, 2026.

Companies that name MYGN in their SEC reports

MYGN company outlook (results filed Jul 30, 2026)

• “Below is a table summarizing Myriad Genetics' full-year 2026 financial guidance*: (in millions, except percentages) 2026 Guidance FY 2026 Comments Revenue $770 - $790 Revised the full-year 2026 revenue range lower, reflecting Q2 results and current business trends.”
• “Adjusted Gross Margin %** 66% - 67% Gross margins expected to fluctuate quarter to quarter given product mix and pricing trends. * Assumes currency rates as of July 30, 2026. ** Adjusted Gross Margin is defined as Gross Margin plus non-cash cost of sales, such as amortization of intangible assets and share-based compensation expense, and non-recurring one-time expenses.”
• “As a result of second quarter 2026 performance and strategic initiatives that are underway, Myriad Genetics is suspending its previous full-year 2026 Adjusted EBITDA guidance and is providing full-year 2026 financial guidance only with respect to Revenue and Adjusted Gross Margin % as set forth above.”

Quoted word-for-word from the SEC 8-K results press release.

MYGN analyst estimates and revisions

MYGN options: expected move

Options price a move of about ±26.9% (±$1.55) by Nov 20, 2026, which includes earnings on Nov 4, 2026. Over the last 8 reports the stock moved ±24.1% on average.

30-day implied volatility 109.8% vs 105.1% realized over the last 30 trading days. Put/call ratio (volume) 0.14. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 23, 2026 at 15:07 UTC)

Technical Analysis (MYGN)

Nexqual's technical model rates MYGN "BUY" based on 5 bullish and 3 bearish signals across 128 daily candles, as of October 23, 2026 at 15:07 UTC.

Analyst Ratings (MYGN)

Wall Street analysts rate MYGN "Hold" based on 9 analysts, with a mean price target of USD 4.49 (range USD 2.5–8), per Nexqual as of October 23, 2026 at 15:07 UTC.

Earnings (MYGN)

Recent Earnings History

Source: Nexqual, October 23, 2026 at 15:07 UTC.

Financials & Fundamentals (MYGN)

Source: Nexqual, October 23, 2026 at 15:07 UTC.

Financial Health Score (MYGN)

Nexqual rates Myriad Genetics, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 15:07 UTC.

Ownership (MYGN)

Source: Nexqual, October 23, 2026 at 15:07 UTC.

Leadership (MYGN)

Myriad Genetics, Inc. is led by Samraat S. Raha, President, CEO & Director, per Nexqual as of October 23, 2026 at 15:07 UTC.

Major Backers & Investors (MYGN)

Notable institutional backers of Myriad Genetics, Inc. include Millennium Management, Vestal Point Capital, LP, Shaw D.E. & Co., Inc., according to Nexqual as of October 23, 2026 at 15:07 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 23, 2026 at 15:07 UTC.

From Myriad Genetics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-24)

Key Strengths & Strategy (as disclosed to the SEC)

• Foundational to our long-term strategy is the development of an end-to-end digital architecture that connects patients, providers, and payers.
• We believe that engaging with providers and patients throughout their consumer and patient journey will better enable us to execute our strategies and fulfill our mission.
• Our long-term growth strategy is built on leveraging our differentiated strengths, including our reputation for trusted high-quality tests and customer service, and our established, extensive commercial reach in community medicine.
• We believe Myriad's ultra-sensitive Precise MRD offering, combined with our growing portfolio of other relevant diagnostic tests that are a common part of cancer care and, our commercial leadership in serving community medicine, will enable us to establish and grow a meaningful MRD business over the coming years.

Partnerships

• In early 2025, we entered into a strategic collaboration with PATHOMIQ, Inc. pursuant to which we obtained exclusive U.S. licensing rights to PATHOMIQ's AI-enabled diagnostic platform, PATHOMIQ_PRAD, to enhance our oncology portfolio and offer AI-driven prognostic and predictive solutions for prostate cancer care.
• In September 2025, we entered into a strategic collaboration with SOPHiA GENETICS S.A. to develop a global liquid biopsy companion diagnostic solution.

Legal & Regulatory Risks (Item 1A, quoted)

• Our actual or perceived failure to comply with data protection laws and regulations could lead to complaints, government enforcement actions, private litigation, and/or adverse publicity and could negatively affect our business.
• We may from time to time be subject to government investigation(s), the unfavorable outcome of which may have a material adverse effect on our financial condition, results of operations and cash flows.
• Changes in health care policy could increase our costs and impact sales of and reimbursement for our tests.
• Our business could be harmed by the loss, suspension, or other restriction of a license, certification, or accreditation, or by the imposition of a fine or penalties, under CLIA, its implementing regulations, or other state, federal and foreign laws and regulations affecting licensure or certification, or by future changes in these laws or regulations.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 15:07 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt